Keynote 024 Updated. We report an updated os and tolerability analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to pembrolizumab. A multicentre, international, randomised, open.

We report an updated os and tolerability analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to pembrolizumab. A multicentre, international, randomised, open.